Quick answer: Semaglutide (our GLP-1SG) and retatrutide (our GLP-3RT) sit at opposite ends of the same research family. Semaglutide activates one receptor, GLP-1. Retatrutide activates three: GLP-1, GIP, and glucagon. Semaglutide is the established single-agonist reference compound with the deepest published record. Retatrutide is the newer triple agonist that has produced the largest effects reported so far in the incretin literature, and it is currently the fastest-growing compound in peptide research.
We have already compared semaglutide with tirzepatide and tirzepatide with retatrutide. This guide closes the triangle: the single agonist against the triple agonist, in plain English, with the published data and the practical lab differences laid out side by side.
First, a 30-Second Crash Course
Three terms carry this whole article:
- Receptor: a lock on the surface of a cell. When the right key fits, the cell receives a signal.
- Agonist: a key that turns the lock ON. A single agonist turns one lock; a triple agonist is one molecule shaped to turn three different locks.
- Incretin system: the gut-hormone signaling network (GLP-1 and GIP are the two main incretins) that the body uses to regulate blood sugar and appetite signaling. Glucagon is a related hormone that governs energy release from stored fuel. Both compounds here were built to study this system.
Retatrutide vs Semaglutide at a Glance
| Semaglutide (GLP-1SG) | Retatrutide (GLP-3RT) | |
|---|---|---|
| Receptors activated | GLP-1 only | GLP-1 + GIP + glucagon |
| Class | Single agonist | Triple agonist |
| Length | 31 amino acids | 39 amino acids |
| Backbone derived from | Human GLP-1 | Human GIP |
| Development code | NN9535 | LY3437943 |
| Published stage | Completed Phase 3 programs, extensive literature | Phase 2 published, Phase 3 (TRIUMPH) ongoing |
| ARG research sizes | 5mg | 20mg, 24mg, 48mg |
What Is Semaglutide (GLP-1SG)?
Semaglutide is a 31-amino-acid analog of human GLP-1, engineered for a long circulating half-life. Two changes do most of the work: a substitution at position 8 that protects the peptide from the DPP-4 enzyme that normally degrades native GLP-1 within minutes, and a fatty-acid side chain that binds albumin in the bloodstream, extending the half-life to roughly one week.
Because it engages only the GLP-1 receptor, semaglutide is the cleanest tool available for studying GLP-1 pharmacology in isolation. Every effect it produces can be attributed to one receptor system, which is exactly why it became the reference compound that every later incretin peptide is measured against. Our GLP-1SG research guide covers its structure and history in depth.
What Is Retatrutide (GLP-3RT)?
Retatrutide is a 39-amino-acid peptide built on a GIP backbone and engineered to activate three receptors at once: GLP-1, GIP, and glucagon. Like semaglutide it carries a fatty-acid side chain for albumin binding and a half-life in the range of about six days.
Its receptor profile is deliberately unbalanced. In published in vitro work, retatrutide is a more potent agonist at the GIP receptor than at the GLP-1 receptor, and weaker again at the glucagon receptor. That asymmetry is by design: the glucagon component is thought to contribute to energy expenditure while the incretin components handle appetite and glucose signaling, and the balance between them is one of the most active questions in the field. The full story is in our GLP-3RT research guide.
So What Is the Real Difference?
It is tempting to say “retatrutide does what semaglutide does, plus two more receptors,” and as a first approximation that is right. But the two compounds differ in kind, not just degree:
- Semaglutide isolates one variable. If a study needs to know what GLP-1 receptor activation does on its own, semaglutide is the tool. Retatrutide cannot answer that question because three signals are always active together.
- Retatrutide studies interaction. Its value is precisely that it engages three systems simultaneously, letting researchers ask whether combined activation produces effects different from the sum of the parts.
- Different backbones. Semaglutide is GLP-1 shaped; retatrutide is GIP shaped. They are not one molecule with additions bolted on, they are structurally distinct peptides that happen to share one target receptor.
- Different depth of evidence. Semaglutide has more than a decade of published human data across multiple large programs. Retatrutide has one published Phase 2 program and an ongoing Phase 3. Anyone comparing the two should keep that asymmetry in mind.
What the Published Studies Say
Both compounds have been studied in large clinical programs, and the published outcomes are the reason the two names come up together so often.
Semaglutide: in the STEP 1 trial (published in the New England Journal of Medicine in 2021), participants receiving the highest studied dose over 68 weeks showed a mean body-weight change of roughly 15%, against about 2% for placebo. Multiple further trials in the STEP and SUSTAIN programs have reproduced GLP-1-driven effects on weight and glycemic markers, which is why semaglutide anchors the modern incretin literature.
Retatrutide: the Phase 2 trial (New England Journal of Medicine, 2023) reported mean body-weight changes at 48 weeks of about 17% at 4 mg, 23% at 8 mg, and 24% at 12 mg, with the curves still declining at the end of the study period. Those are the largest effects reported for any incretin-family peptide to date, and they are the reason retatrutide has become the most-watched compound in the category. Phase 3 (the TRIUMPH program) is under way and will determine whether those results hold in larger populations.
Two cautions when reading numbers like these side by side. The trials used different durations, populations, and designs, so the figures are not a direct head-to-head. And these results describe clinical research programs; they say nothing about laboratory use of the research-grade peptides discussed here, which are supplied strictly for in vitro and laboratory work.
Handling Notes (the Practical Stuff)
On the bench the two behave similarly. Both arrive as lyophilized powder in sealed vials, both are reconstituted with bacteriostatic water, and both should be treated as delicate molecules: introduce the diluent slowly down the vial wall, never shake, and refrigerate once reconstituted. Our storage and stability guide covers the details, and the reconstitution calculator handles the volume math for any vial size.
The one practical difference is scale. Semaglutide is supplied as a 5mg vial; retatrutide research typically calls for larger masses, which is why GLP-3RT is offered in 20mg, 24mg, and 48mg formats.
Which One Belongs in Which Project?
- Studying GLP-1 receptor pharmacology on its own: semaglutide. It is the single-variable reference compound.
- Studying multi-receptor interaction, GIP biology, or the glucagon component: retatrutide. It is the only compound in the family that brings all three.
- Benchmarking a new compound: semaglutide, because the comparison literature is deepest.
- Building a complete incretin reference set: both, with tirzepatide (GLP-2TZ) as the dual-agonist middle step.
Frequently Asked Questions
Is retatrutide the same as semaglutide?
No. Semaglutide is a single GLP-1 receptor agonist built on a GLP-1 backbone. Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors built on a GIP backbone. They share one target receptor but are structurally different peptides.
Is retatrutide stronger than semaglutide?
In published clinical trials, retatrutide produced larger mean body-weight changes than semaglutide did in its own trials, roughly 24% at 48 weeks versus about 15% at 68 weeks. The trials were not head-to-head, so the figures are not directly comparable, and retatrutide has far less published data overall.
Why does retatrutide activate the glucagon receptor?
Glucagon signaling is associated with energy expenditure, while GLP-1 and GIP signaling are associated with appetite and glucose regulation. Combining all three in one molecule lets researchers study whether the pathways reinforce one another, which is the central hypothesis behind triple-agonist design.
Which is better for research?
Neither is better in the abstract. Semaglutide isolates a single receptor, which makes it ideal for clean single-variable studies and benchmarking. Retatrutide is the tool for studying multi-receptor interaction. Most incretin reference catalogs include both.
What research sizes does ARG Peptides offer?
GLP-1SG (semaglutide) is supplied as a 5mg lyophilized vial. GLP-3RT (retatrutide) is supplied in 20mg, 24mg, and 48mg lyophilized vials. All are 99% HPLC-verified and supplied for laboratory research use only.
FOR LABORATORY RESEARCH USE ONLY: ARG Peptides products are research chemicals sold strictly for in vitro and laboratory research. They are not intended for human or animal consumption, and no therapeutic or medical claims are made or implied. Clinical trial results described above relate to pharmaceutical development programs and do not describe or endorse any use of research-grade material.
Research compounds discussed in this guide: GLP-3RT (Retatrutide) · GLP-1SG (Semaglutide) · GLP-2TZ (Tirzepatide). All for laboratory research use only.